Alpha-Adrenoceptor Vascular Function In Chronic Kidney Disease Focus On The Role Of Endothelial Nitric Oxide
Chronic Kidney Disease, Hypertension
About this trial
This is an interventional other trial for Chronic Kidney Disease focused on measuring Blood Pressure Nitric Oxide, L-NMMA, Phenylephrine, Vasoreactivity, Blood Pressure
Eligibility Criteria
Inclusion Criteria: Men and Women-18 to 55 years of age. There are three groups of volunteers. Group A. People who are hypertensive with kidney disease. When not taking blood pressure medicines, blood pressure must have a systolic between 140-170 mmHg. Diastolic must be between 90-109 mmHg.Kidney function should be around half of normal. Urine protein must be no more than 1 gram in a 24-hour urine time period. Group B. People who are hypertensive without kidney disease. Blood pressure must have a systolic between 140-170 mmHg. Diastolic must be between 90-109 mmHg. Kidney function should be normal. Normal amounts of protein in their urine. Group C. People who are normotensive. Blood pressure must have a systolic below 131/mmHg. Diastolic must be below 81 mmHg. Kidney function should be normal. No more than normal amounts of protein in their urine. Exclusion Criteria: People with: Diabetes Lung disease Stomach disease Liver disease Blood vessel disease Heart disease Hereditary blood disorders Hematocrit (amount of red blood cells) less than 30% Current tobacco use Kidney disease who require dialysis Women who are pregnant or breastfeeding
Sites / Locations
- University of Michigan Hospital
Arms of the Study
Arm 1
Arm 2
Arm 3
Experimental
Active Comparator
Active Comparator
CKD
Hypertension group
Normotensive group